Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.
Recruiting
N/A
Interventional Study
Prostate Cancer
Radiotherapy Side Effect
Hypofractionation
Brachytherapy
Radiotherapy
Localized Prostate Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 95
- Sex
- Male
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 205 (estimated)
- Sponsor
- CHU de Quebec-Universite Laval · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wise. Acceptability, tolerability, acute and late toxicity will be reported. MRI visible dominant intra-prostatic lesion w…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Biopsy proven Prostate adenocarcinoma
* Stage T1c, T2 (Annex 2)
* Stage Nx or N0
* Stage Mx or M0
* PSA \< 20ng/ml
* Gleason Score 6 or 7
* Having the ability to sing a written consent
Exclusion Criteria:
* Age \< 18ans
* Clinical Stage T3 or T4
* Stage N1
* Stage M1
* PSA \…
Contacts